Envista (NVST) CMD 2025 summary

Strategic Priorities and Business Outlook

• Focused on growth, operations, and people, with disciplined execution and a reset of targets following management changes in 2023.

• Portfolio centers on attractive dental market segments, leveraging innovation, global reach, and continuous improvement via the Envista Business System (EBS).

• Expanded capital allocation includes a $250 million share buyback program, M&A, and commitment to financial guidance.

• Emphasis on commercial execution, capital efficiency, and talent development to align performance with potential.

• Operational excellence driven by EBS, with Kaizen initiatives and productivity improvements across manufacturing and G&A.

Market Environment and Growth Drivers

• Dental market valued at $400 billion, expected to return to 3%-5% annual growth after post-COVID volatility.

• Growth supported by secular trends: aging populations, rising living standards, increased demand for aesthetics, digitization, and expanding access.

• Supply constraints, such as limited numbers of clinicians, continue to drive consistent market growth.

• Focus on high-margin, fast-growing specialty segments: implants and orthodontics, with leadership positions in both.

• Balanced revenue by category and geography, with global operations in over 130 countries.

Business Unit Strategies and Innovation

• Implant business (Nobel Biocare) targets both premium and challenger segments, leveraging brand heritage, innovation, and digital workflows.

• Recent investments in commercial execution, clinical education, and product innovation have returned the implant business to growth after eight quarters of decline.

• Orthodontics (Ormco) leverages leadership in both fixed appliances and clear aligners, with Spark aligners surpassing 800,000 cases and ongoing cost reductions.

• Ormco's digital platform integrates aligners and brackets, with plans to launch mixed-modality treatments in 2025.

• Continuous pipeline of new products and digital solutions, with robust R&D investment and partnerships for clinical education.